A5062272413- Natural Language Processing Techniques
- Topic Modeling
- Hepatocellular Carcinoma Treatment and Prognosis
- Protein Hydrolysis and Bioactive Peptides
- Probiotics and Fermented Foods
- Antimicrobial Peptides and Activities
- Knee injuries and reconstruction techniques
- Liver Disease Diagnosis and Treatment
- Total Knee Arthroplasty Outcomes
- Membrane Separation Technologies
- Electrospun Nanofibers in Biomedical Applications
- Enzyme-mediated dye degradation
- biodegradable polymer synthesis and properties
- Speech and dialogue systems
- Biofuel production and bioconversion
- Semantic Web and Ontologies
- Periodontal Regeneration and Treatments
- Sports injuries and prevention
- Enzyme Production and Characterization
- melanin and skin pigmentation
- Bone Tissue Engineering Materials
- Liver Disease and Transplantation
- Microbial Metabolic Engineering and Bioproduction
- Biochemical and Structural Characterization
- Cholangiocarcinoma and Gallbladder Cancer Studies
Matsuyama Red Cross Hospital
2023-2025
Niigata University
2014-2024
Okayama University Hospital
2018-2024
University of Fukui
2024
Okayama University
1995-2023
Ehime Prefectural Central Hospital
2021-2023
Kagawa University
2023
Shimane University
2023
Shimonoseki City Hospital
2023
Hiroshima University Hospital
2023
A growing body of evidence suggests that non-viral hepatocellular carcinoma (HCC) might benefit less from immunotherapy.We carried out a retrospective analysis prospectively collected data consecutive patients with advanced HCC, treated atezolizumab plus bevacizumab, lenvatinib, or sorafenib, in 36 centers 4 countries (Italy, Japan, Republic Korea, and UK). The primary endpoint was overall survival (OS) bevacizumab versus lenvatinib. Secondary endpoints were progression-free (PFS) OS PFS...
This paper presents a construction-inspecific model of multiword expression decomposability based on latent semantic analysis. We use analysis to determine the similarity between and its constituent words, claim that higher similarities indicate greater decomposability. test over English noun-noun compounds verb-particles, evaluate correlation with hyponymy values in WordNet. Based mean partitions data ranked similarity, we furnish evidence for calculated being correlated relational content
Fibrin clot membranes prepared from advanced platelet-rich fibrin (A-PRF) or concentrated growth factors (CGF), despite their relatively rapid biodegradability, have been used as bioactive barrier for alveolar bone tissue regeneration. As the degrade, it is thought that are gradually released. However, mechanical and degradable properties of these not well characterized. The purpose this study was to mechanically chemically characterize membranes. A-PRF CGF clots were blood samples collected...
Platelet-rich fibrin (PRF) was developed as an advanced form of platelet-rich plasma to eliminate xenofactors, such bovine thrombin, and it is mainly used a source growth factor for tissue regeneration. Furthermore, although minor application, PRF in compressed membrane-like has also been substitute commercially available barrier membranes guided-tissue regeneration (GTR) treatment. However, the membrane resorbed within 2 weeks or less at implantation sites; therefore, can barely maintain...
Atezolizumab plus bevacizumab (Atez/Bev) treatment is recommended for unresechepatocellular carcinoma (u-HCC) patients classified as Child-Pugh A (CP-A). This study aimed to elucidate the prognosis of treated with Atez/Bev, especially CP-A and -B cases.From September 2020 March 2022, 457 u-HCC Atez/Bev were enrolled (median age 74 years, male:female = 368:89, CP-A:CP-B 427:30, score [CPS] 5:6:7:8:9 271:156:21:8:1). Therapeutic response was evaluated using RECIST ver.1.1. Clinical features...
To investigate whether neutrophil-to-lymphocyte ratio (NLR) can predict outcomes in patients with unresectable hepatocellular carcinoma (HCC) treated atezolizumab plus bevacizumab (Atez/Bev).A total of 249 HCC Atez/Bev were included. We analyzed survival and discontinuation this therapy cohort.Cumulative overall at 2, 4, 6, 8 months was 97.6%, 94.9%, 88.9%, 82.8%, respectively. Cumulative differed significantly between low (<3.0) versus high (≥3.0) NLR (P = 0.001). Conversely, cumulative...
A chicken embryo sternal cartilage cDNA library, created in the plasmid expression vector pUC9, was screened for sequences coding immunologically detectable core protein of large, major proteoglycan cartilage. 1229-base-pair clone isolated that contained only one extended open reading frame, which had a polypeptide 379 amino acid residues. These deduced corresponded to those anticipated from current models structure; sequence encompassing 21 acids almost identical known bovine nasal...
Rice (Oryza sativa) is consumed as a staple food globally, and rice bran, the byproduct, an unused biomass that ultimately discarded waste. Thus, in present study, technique for producing tyrosinase inhibitory peptides from bran protein (RBP) was developed. Simultaneous treatment of RBP with chymotrypsin trypsin produced numerous peptides. Subsequently, six were isolated hydrolysate fractions multistep purification protocol, their amino acid sequences determined. Three these had C-terminal...
It was recently reported that hepatocellular carcinoma (HCC) patients with non-alcoholic steatohepatitis (NASH) are not responsive to immune-checkpoint inhibitor (ICI) treatment. The present study aimed evaluate the therapeutic efficacy of lenvatinib in fatty liver disease (NAFLD)/NASH-related unresectable-HCC (u-HCC). Five hundred thirty u-HCC Child-Pugh A were enrolled, and divided into NAFLD/NASH (n = 103) Viral/Alcohol 427) groups. Clinical features compared a retrospective manner....
A comparison of therapeutic efficacy between atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib treatment given as first-line therapy for unresectable hepatocellular carcinoma (u-HCC) in regard to progression-free survival (PFS) overall (OS) has not been reported. We aimed elucidate which those initial u-HCC greater prognostic impact on PFS OS affected patients, retrospectively.From 2020 January 2022, 251 (Child-Pugh A, ECOG PS 0/1, BCLC-B/C) treated were enrolled (Atez/Bev-group, n =...
The present study focused on the association of early bevacizumab (Bev) interruption with clinical outcome atezolizumab plus bevacizumab.This retrospective included 239 patients advanced hepatocellular carcinoma receiving atezolizumab/Bev from September 2020 to June 2021 at 16 different institutions in Japan. We conducted a 9-week landmark analysis investigate Bev due adverse events therapeutic efficacy.The median age was 73.0 (68.0-80.0) years old, 195 (81.6%) men. objective response rate...
Abstract Purpose This study investigated the safety and efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) re-administration after recovery from EGFR-TKI-induced interstitial lung disease (ILD). Methods multicenter retrospective collected data consecutive advanced NSCLC patients who underwent EGFR-TKI ILD. Results Fifty-eight were registered. The grades initial TKI-induced ILD grade 1 to 4. TKIs used for erlotinib 15 patients, osimertinib 15, gefitinib 14,...
Although systemic therapy is recommended for patients with multiple intermediate stage unresectable hepatocellular carcinoma (u-HCC) classified as beyond the up-to-7 criteria (UT-7 out/multiple) a transcatheter arterial chemoembolization (TACE) unsuitable condition, few reports have examined therapeutic efficacy of atezolizumab plus bevacizumab combination (Atez/Bev) in such cases. This study aimed to elucidate response Atez/Bev u-HCC UT-7 out/multiple.From September 2020 2021, 95 Japanese...